30 Biotech LargeCap Firms

Components Performance/Risk
Period Return
62.5%
Return Rank
Strong
Risk Exposure
Above Average

The Biotechnology Top 30 firms includes the largest biotech firms by market cap > $10bn, listed on the NASDAQ and NYSE stock exchanges

 

Momentum highlights the trend of the average price computed over a week, compared to the monthly price average, and is indicative of the sector's resilience

Share performances can be ranked by selected time frame, from 2 weeks to one year (default), by selection  in the top-right menu

View the Analytics for fundamental ratio details 

The companion theme of 30 Biotech LargeCap Firms is the selection of the Next 50 MidCap Biotech firms

The top 100 Biotech Firms by market cap are also listed

 

The iShares Biotechnology ETF  composed of an extensive list of biotechnology and pharmaceutical equities - is the benchmark of this theme

The biotech selection of the top 30 by market cap is not weighted - assuming one share of each component had been invested at the beginning of the selected period

 

ABIVAX  , a French  clinical-stage biotechnology company, and Praxis Precision Medicines have been set aside because of exceptional out-of-range performance (after repricing in July 2025 and October 2025)

 

Actual performance of , the tracker fund, maybe higher or lower, depending on the weighting and selection decided by the provider

Check the information available on the iShares Biotechnology ETF site or contact your advisor

Performance History
Components Performance/Risk
Weights by Industry
Industry Performance/Risk